Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
    • MEDICAL CANNABIS
      • SCIENCE
      • LEGALISED MARKETS
  • RESEARCH
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL TRIALS
      • AUTISM
      • INSOMNIA
      • CHRONIC PAIN
  • PRODUCTS
    • Doctors
    • Pharmacists
    • Patients
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
    •         - MEDICAL CANNABIS
      •                 - SCIENCE
      •                 - LEGALISED MARKETS
  • RESEARCH
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL TRIALS
      •                 - AUTISM
      •                 - INSOMNIA
      •                 - CHRONIC PAIN
  • PRODUCTS
    •         - Doctors
    •         - Pharmacists
    •         - Patients
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

Significant Anti-Cancer Effect Observed in Pre-Clinical Studies

By Zelira TherapeuticsNovember 30, 2016articles-2016

Significant Anti-Cancer Effect Observed in Pre-Clinical Studies

Zelda Expands Intellectual Property Portfolio
Zelda Therapeutics Enters Into Collaboration Agreement with Prestigious Telethon Kids Institute

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics
30 Jul

Zelira has released its most recent quarterly report for the 2021 financial year.

The Q4 highlights include strong growth on Q3 cash receipts (+38%), accelerating commercialisation and the achievement of significant research milestones.

Read more here:
http://ow.ly/xleR50FGLmK

Twitter 1420955741767208960
Load More...

CONTACT US

    Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.